A healthcare AI company called Midjourney Medical announced on June 17 that it has built a whole-body ultrasound scanner powered by artificial intelligence that can complete a full-body scan in sixty seconds at a cost of two to three dollars per session. The device uses 8,960 transducers — the sensors that emit and receive ultrasound signals — and is designed to operate without the specialist training typically required for medical ultrasound equipment.

The company has raised more than 74 million dollars in funding and developed the scanner in partnership with Butterfly Network, the ultrasound technology firm that has been working on miniaturised ultrasound hardware since its founding in 2011. Midjourney Medical’s device combines Butterfly’s transducer array technology with AI analysis software that interprets the scan output and flags areas that may require follow-up clinical attention.

The pricing model targets a level far below what medical imaging currently costs. A standard MRI in the United States runs between one thousand and three thousand dollars out of pocket. A CT scan typically costs several hundred dollars. A full-body ultrasound protocol administered by a trained sonographer is cheaper than either but still well above what Midjourney Medical is targeting with this product.

The company has positioned the device as a preventive health screening tool rather than a diagnostic replacement for physician-ordered imaging. The sixty-second scan produces a data set that the AI software analyses for common anatomical anomalies. Results are intended to be reviewed by a clinician who can then order follow-up imaging where the software flags a concern.

Medical AI products face significant regulatory requirements before clinical use in most markets. The FDA clearance process for a device like this requires demonstrating that the AI diagnostic layer performs safely and accurately across diverse patient populations. Midjourney Medical has not disclosed its FDA pathway timeline, though the June 17 announcement indicates the product is well into development.

At 8,960 transducers, the hardware specification is significantly more complex than existing portable ultrasound devices on the market. Butterfly’s existing single-chip handheld uses a different architecture and is already FDA-cleared for specific limited clinical applications, providing a regulatory baseline from which the Midjourney Medical partnership builds.

More on AI in healthcare and medical technology investments is in our tech section. Butterfly Network’s background is detailed on the Butterfly Network website. Our coverage of AI diagnostics and preventive health platforms tracks this growing category. The health technology investment landscape in 2026 is in our AI and tech archives.